| Multiple Sclerosis |
1 |
1 |
| Vaccines |
0 |
0.54 |
| Infectious Mononucleosis |
0 |
0.53 |
| Human Papillomavirus |
0 |
0.48 |
| Biologic Therapy |
0 |
0.45 |
| Cancer |
0 |
0.45 |
| Multiple Sclerosis Risk |
0 |
0.45 |
| Herpes Zoster |
0 |
0.36 |
| Board Certification |
0 |
0.23 |
| Child |
0 |
0.23 |
| Genetics |
0 |
0.23 |
| Virology |
0 |
0.23 |
| Herpes Simplex |
0 |
0.14 |
| Toxicology |
0 |
0.13 |
| Genomic Medicine |
0 |
0.12 |
| Antigens |
0 |
0.11 |
| Autoimmune Disease |
0 |
0.11 |
| Clinical Research |
0 |
0.11 |
| Diet |
0 |
0.11 |
| Epstein-Barr Virus |
0 |
0.99 |
| Herpes Zoster Vaccine |
0 |
0.11 |
| Immunization |
0 |
0.11 |
| Lupus |
0 |
0.11 |
| Major Histocompatibility Complex |
0 |
0.11 |
| Monoclonal Antibody |
0 |
0.11 |
| Pandemic |
0 |
0.11 |
| Papillomavirus |
0 |
0.11 |
| Plantar |
0 |
0.11 |
| Polio |
0 |
0.11 |
| Pollutant |
0 |
0.11 |
| Students |
0 |
0.11 |
| Therapeutic Vaccine |
0 |
0.11 |
| Varicella-Zoster Virus |
0 |
0.11 |
| Young Adult |
0 |
0.11 |
| Cervical Cancer |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.03 |
| Systemic Lupus Erythematosus |
0 |
0.03 |